SCHEMBL10243614

SCHEMBL10243614

CCN(CCNC(=O)OC)[C@@H](C)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 3/20 0.42
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
GPR139 Q6DWJ6 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
MAPK14 Q16539 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CCR2 P41597 1/20 0.39
CES2 O00748 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282707 0.89 CCR2 (0.39) MCHR1ALDH1A1CCR2
SCHEMBL10244115 0.86 MCHR1 (0.42) MCHR1MEN1KMT2ALMNA
SCHEMBL10243833 0.85 CYP2C19 (0.43) MEN1KMT2ACYP2C9GPR139KDM4E
SCHEMBL10243821 0.84 OPRK1 (0.46) GAALMNAKDM4E
SCHEMBL10244077 0.84 CYP2C19 (0.42) ALDH1A1KMT2ACYP3A4CYP2C9
SCHEMBL10243624 0.83 ACHE (0.37) ALDH1A1CYP3A4LMNAKDM4E
SCHEMBL10243429 0.83 MTNR1A (0.47)
SCHEMBL10243851 0.83 MTNR1A (0.47)
SCHEMBL10244397 0.83 MTNR1A (0.47)
SCHEMBL10243444 0.83 RAB9A (0.45) ALDH1A1NPSR1GAASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MCHR1 344/4885ALDH1A1 1939/4885POLB 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.